Victoza® (liraglutide) – New indication, new warning
August 25, 2017 – Novo Nordisk announced the FDA approval of Victoza (liraglutide), to reduce the risk of major adverse cardiovascular (CV) events [CV death, non-fatal myocardial infarction (MI), or non-fatal stroke] in adults with type 2 diabetes mellitus (T2DM) and established CV disease.
Top